DE602004017966D1 - Neue aminopyridinderivate als mglur5-antagonisten - Google Patents

Neue aminopyridinderivate als mglur5-antagonisten

Info

Publication number
DE602004017966D1
DE602004017966D1 DE602004017966T DE602004017966T DE602004017966D1 DE 602004017966 D1 DE602004017966 D1 DE 602004017966D1 DE 602004017966 T DE602004017966 T DE 602004017966T DE 602004017966 T DE602004017966 T DE 602004017966T DE 602004017966 D1 DE602004017966 D1 DE 602004017966D1
Authority
DE
Germany
Prior art keywords
pyridine derivatives
new amino
mglur5 antagonists
mglur5
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004017966T
Other languages
German (de)
English (en)
Inventor
Christelle Bolea
Vincent Mutel
Jean-Philippe Rocher
Anne-Sophie Bessis
Poul Emmanuel Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Addex Pharmaceuticals SA
Original Assignee
Addex Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0304901A external-priority patent/GB0304901D0/en
Priority claimed from GB0316430A external-priority patent/GB0316430D0/en
Application filed by Addex Pharmaceuticals SA filed Critical Addex Pharmaceuticals SA
Publication of DE602004017966D1 publication Critical patent/DE602004017966D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602004017966T 2003-03-04 2004-03-04 Neue aminopyridinderivate als mglur5-antagonisten Expired - Lifetime DE602004017966D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0304901A GB0304901D0 (en) 2003-03-04 2003-03-04 Novel aminopyridine derivatives as mGIuR5 antagonists
GB0316430A GB0316430D0 (en) 2003-07-14 2003-07-14 Aminopyridine derivatives
PCT/IB2004/000745 WO2004078728A1 (en) 2003-03-04 2004-03-04 NOVEL AMINOPYRIDINE DERIVATIVES AS mGIuR5 ANTAGONISTS

Publications (1)

Publication Number Publication Date
DE602004017966D1 true DE602004017966D1 (de) 2009-01-08

Family

ID=32964064

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017966T Expired - Lifetime DE602004017966D1 (de) 2003-03-04 2004-03-04 Neue aminopyridinderivate als mglur5-antagonisten

Country Status (16)

Country Link
US (2) US7205411B2 (cg-RX-API-DMAC7.html)
EP (2) EP2028180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006519251A (cg-RX-API-DMAC7.html)
AT (1) ATE415390T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004218180B2 (cg-RX-API-DMAC7.html)
CA (1) CA2517083A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108837T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004017966D1 (cg-RX-API-DMAC7.html)
DK (1) DK1603877T3 (cg-RX-API-DMAC7.html)
ES (1) ES2316968T3 (cg-RX-API-DMAC7.html)
PL (1) PL1603877T3 (cg-RX-API-DMAC7.html)
PT (1) PT1603877E (cg-RX-API-DMAC7.html)
RU (1) RU2330020C2 (cg-RX-API-DMAC7.html)
SI (1) SI1603877T1 (cg-RX-API-DMAC7.html)
UA (1) UA81464C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004078728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
AU2006240217A1 (en) * 2005-04-22 2006-11-02 Merck & Co., Inc. Phenyl ethyne compounds
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
DE102005062987A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
EP2272509A1 (en) * 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
EA201391348A8 (ru) 2011-03-18 2014-11-28 Новартис Аг КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028963A (ja) * 1983-07-27 1985-02-14 Takeda Chem Ind Ltd 置換ビニル誘導体
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
NZ525917A (en) 2000-12-04 2005-11-25 F Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists and their use in treating mGLuR5 receptor mediated disorders

Also Published As

Publication number Publication date
AU2004218180B2 (en) 2009-11-12
EP1603877A1 (en) 2005-12-14
DK1603877T3 (da) 2009-03-09
RU2330020C2 (ru) 2008-07-27
US20080004316A1 (en) 2008-01-03
ES2316968T3 (es) 2009-04-16
PT1603877E (pt) 2009-02-11
EP2028180A1 (en) 2009-02-25
RU2005130647A (ru) 2006-04-10
US20060030601A1 (en) 2006-02-09
UA81464C2 (en) 2008-01-10
CA2517083A1 (en) 2004-09-16
ATE415390T1 (de) 2008-12-15
AU2004218180A1 (en) 2004-09-16
PL1603877T3 (pl) 2009-05-29
EP1603877B1 (en) 2008-11-26
SI1603877T1 (sl) 2009-04-30
WO2004078728A1 (en) 2004-09-16
CY1108837T1 (el) 2014-07-02
US7205411B2 (en) 2007-04-17
JP2006519251A (ja) 2006-08-24

Similar Documents

Publication Publication Date Title
DE69318854D1 (de) Spiroazacyclischderivate als substanz p antagonisten
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
DE69328975D1 (de) Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
DE602004017213D1 (de) Allosterische modulatoren von metabotropen glutamatrezeptoren
MY135686A (en) Indole derivatives useful as histamine h3 antagonists
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
SE0201635D0 (sv) Novel compounds
DE69616480D1 (de) Piperidinderivate als neurokininantagonisten
CY1111858T1 (el) Ετεροκυκλικα παραγωγα ως διαμορφωτες υποδοχεα οπιοειδων
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
DE602005025672D1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
ATE392415T1 (de) 3-azabicyclo(3.1.0)hexan derivative als antagonisten der opioid rezeptoren
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5
EA200801734A1 (ru) Производные n-тиазол-2-илбензамида
ATE429421T1 (de) Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
BG105710A (en) 5ht1 antagonists for antidepressant therapy
DK1254905T3 (da) 4-(2-pyridyl)piperiziner med 5HT7 receptoragonistaktivitet
NO20081529L (no) Naftyridinderivater
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
ATE383343T1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
EP1496059A4 (en) CONDENSED BICYCLIC PYRIMIDINE DERIVATIVES
EA200401099A1 (ru) Производные гетероциклического амида
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems

Legal Events

Date Code Title Description
8364 No opposition during term of opposition